Jinling Pharmaceutical Co Ltd

SHE:000919 China Drug Manufacturers - Specialty & Generic
Market Cap
$626.40 Million
CN¥4.60 Billion CNY
Market Cap Rank
#12268 Global
#3010 in China
Share Price
CN¥7.39
Change (1 day)
-0.27%
52-Week Range
CN¥6.16 - CN¥8.03
All Time High
CN¥16.21
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more

Jinling Pharmaceutical Co Ltd (000919) - Net Assets

Latest net assets as of September 2025: CN¥4.85 Billion CNY

Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) has net assets worth CN¥4.85 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.02 Billion) and total liabilities (CN¥1.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥4.85 Billion
% of Total Assets 80.46%
Annual Growth Rate 12.71%
5-Year Change 41.23%
10-Year Change 65.79%
Growth Volatility 41.33

Jinling Pharmaceutical Co Ltd - Net Assets Trend (1996–2024)

This chart illustrates how Jinling Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jinling Pharmaceutical Co Ltd (1996–2024)

The table below shows the annual net assets of Jinling Pharmaceutical Co Ltd from 1996 to 2024.

Year Net Assets Change
2024-12-31 CN¥4.85 Billion +31.58%
2023-12-31 CN¥3.68 Billion +1.60%
2022-12-31 CN¥3.63 Billion +2.62%
2021-12-31 CN¥3.53 Billion +2.95%
2020-12-31 CN¥3.43 Billion +0.25%
2019-12-31 CN¥3.42 Billion +5.50%
2018-12-31 CN¥3.25 Billion +6.29%
2017-12-31 CN¥3.05 Billion +0.03%
2016-12-31 CN¥3.05 Billion +4.39%
2015-12-31 CN¥2.92 Billion +6.31%
2014-12-31 CN¥2.75 Billion +6.86%
2013-12-31 CN¥2.57 Billion +4.41%
2012-12-31 CN¥2.47 Billion +6.04%
2011-12-31 CN¥2.33 Billion +5.73%
2010-12-31 CN¥2.20 Billion +7.03%
2009-12-31 CN¥2.05 Billion +9.39%
2008-12-31 CN¥1.88 Billion -3.64%
2007-12-31 CN¥1.95 Billion +14.76%
2006-12-31 CN¥1.70 Billion +8.72%
2005-12-31 CN¥1.56 Billion +6.35%
2004-12-31 CN¥1.47 Billion +6.53%
2003-12-31 CN¥1.38 Billion +11.14%
2002-12-31 CN¥1.24 Billion +11.82%
2001-12-31 CN¥1.11 Billion +4.62%
2000-12-31 CN¥1.06 Billion +4.20%
1999-12-31 CN¥1.02 Billion +225.38%
1998-12-31 CN¥312.85 Million +38.47%
1997-12-31 CN¥225.93 Million +32.78%
1996-12-31 CN¥170.16 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jinling Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 165816237300.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥1.66 Billion 43.74%
Common Stock CN¥623.71 Million 16.45%
Other Comprehensive Income CN¥3.09 Million 0.08%
Other Components CN¥1.51 Billion 39.73%
Total Equity CN¥3.79 Billion 100.00%

Jinling Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jinling Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
LYDIA HOLDING A.S.
IS:LYDHO
 		$337.08 Million
Hoang Huy Investment Financial
VN:TCH
 		$337.09 Million
Solvac S.A.
BR:SOLV
 		$337.10 Million
Eton Pharmaceuticals Inc
NASDAQ:ETON
 		$337.18 Million
Clevo Co
TW:2362
 		$336.97 Million
Overstock.com Inc.
LSE:0KDU
 		$336.94 Million
Guizhou Wire Rope Co Ltd
SHG:600992
 		$336.94 Million
Elemental Royalty Corporation Common Stock
NASDAQ:ELE
 		$336.88 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jinling Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,042,611,967 to 3,791,090,837, a change of 748,478,870 (24.6%).
  • Net income of 40,409,795 contributed positively to equity growth.
  • Dividend payments of 63,242,928 reduced retained earnings.
  • Share repurchases of 20,282,577 reduced equity.
  • Other comprehensive income decreased equity by 334,542.
  • Other factors increased equity by 791,929,122.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥40.41 Million +1.07%
Dividends Paid CN¥63.24 Million -1.67%
Share Repurchases CN¥20.28 Million -0.54%
Other Comprehensive Income CN¥-334.54K -0.01%
Other Changes CN¥791.93 Million +20.89%
Total Change CN¥- 24.60%

Book Value vs Market Value Analysis

This analysis compares Jinling Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.16x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 21.89x to 1.16x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1996-12-31 CN¥0.34 CN¥7.39 x
1997-12-31 CN¥0.44 CN¥7.39 x
1998-12-31 CN¥0.62 CN¥7.39 x
1999-12-31 CN¥2.02 CN¥7.39 x
2000-12-31 CN¥2.10 CN¥7.39 x
2001-12-31 CN¥2.13 CN¥7.39 x
2002-12-31 CN¥2.27 CN¥7.39 x
2003-12-31 CN¥2.53 CN¥7.39 x
2004-12-31 CN¥2.67 CN¥7.39 x
2005-12-31 CN¥2.85 CN¥7.39 x
2006-12-31 CN¥3.10 CN¥7.39 x
2007-12-31 CN¥3.50 CN¥7.39 x
2008-12-31 CN¥3.38 CN¥7.39 x
2009-12-31 CN¥3.67 CN¥7.39 x
2010-12-31 CN¥3.90 CN¥7.39 x
2011-12-31 CN¥4.08 CN¥7.39 x
2012-12-31 CN¥4.21 CN¥7.39 x
2013-12-31 CN¥4.37 CN¥7.39 x
2014-12-31 CN¥4.60 CN¥7.39 x
2015-12-31 CN¥4.85 CN¥7.39 x
2016-12-31 CN¥5.04 CN¥7.39 x
2017-12-31 CN¥5.13 CN¥7.39 x
2018-12-31 CN¥5.43 CN¥7.39 x
2019-12-31 CN¥5.71 CN¥7.39 x
2020-12-31 CN¥5.67 CN¥7.39 x
2021-12-31 CN¥5.81 CN¥7.39 x
2022-12-31 CN¥5.94 CN¥7.39 x
2023-12-31 CN¥6.04 CN¥7.39 x
2024-12-31 CN¥6.40 CN¥7.39 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jinling Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.07%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.23%
  • • Asset Turnover: 0.54x
  • • Equity Multiplier: 1.61x
  • Recent ROE (1.07%) is below the historical average (10.42%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1996 18.44% 15.94% 0.80x 1.45x CN¥14.36 Million
1997 41.33% 30.69% 0.98x 1.37x CN¥70.11 Million
1998 31.64% 28.96% 0.78x 1.39x CN¥67.15 Million
1999 11.09% 31.81% 0.30x 1.15x CN¥11.06 Million
2000 11.23% 32.57% 0.30x 1.15x CN¥13.02 Million
2001 10.11% 21.76% 0.35x 1.32x CN¥1.23 Million
2002 11.26% 20.44% 0.41x 1.35x CN¥14.42 Million
2003 10.36% 15.54% 0.52x 1.28x CN¥4.58 Million
2004 8.35% 11.22% 0.56x 1.33x CN¥-22.15 Million
2005 11.00% 12.77% 0.67x 1.28x CN¥14.35 Million
2006 13.00% 14.67% 0.68x 1.31x CN¥46.62 Million
2007 17.42% 19.85% 0.65x 1.34x CN¥131.01 Million
2008 4.85% 4.62% 0.81x 1.29x CN¥-87.76 Million
2009 11.95% 11.23% 0.80x 1.33x CN¥36.02 Million
2010 9.81% 8.92% 0.79x 1.40x CN¥-3.78 Million
2011 8.04% 7.32% 0.76x 1.44x CN¥-40.24 Million
2012 6.76% 6.23% 0.72x 1.51x CN¥-68.68 Million
2013 7.08% 5.98% 0.79x 1.50x CN¥-64.33 Million
2014 8.50% 7.11% 0.77x 1.56x CN¥-34.88 Million
2015 8.51% 6.46% 0.84x 1.58x CN¥-36.30 Million
2016 7.09% 5.03% 0.93x 1.52x CN¥-73.77 Million
2017 5.30% 4.30% 0.83x 1.49x CN¥-121.55 Million
2018 8.83% 8.34% 0.75x 1.42x CN¥-31.90 Million
2019 5.05% 5.73% 0.61x 1.44x CN¥-142.48 Million
2020 3.28% 3.74% 0.58x 1.50x CN¥-192.09 Million
2021 4.12% 4.29% 0.63x 1.52x CN¥-172.15 Million
2022 3.52% 3.94% 0.59x 1.52x CN¥-194.14 Million
2023 3.28% 3.58% 0.61x 1.50x CN¥-204.61 Million
2024 1.07% 1.23% 0.54x 1.61x CN¥-338.70 Million

Industry Comparison

This section compares Jinling Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jinling Pharmaceutical Co Ltd (000919) CN¥4.85 Billion 18.44% 0.24x $336.98 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million